FibroBiologics, Inc.
$0.63 -$0.08 (-11.92%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
From its Mar 6 high, the share price fell 93%.
Peak close $8.70 on Mar 6; trough close $0.63 on Jul 27. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -93% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Mar 31
The stock moved -42.1% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 31 -
Mar 30
The stock moved -42.0% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 30
The story updates itself as events post · The wolf reports; you decide
Snapshot
About FibroBiologics, Inc.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain canc…
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.